Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (21897)	6/5/1998 1:08:00 PM
From: dwight martin	Read Replies (2) \| Respond to of 32384

Henry will undoubtedly respond, but I checked the IBM Patent site and found 2 patents assigned to LGND that had something (what, let Henry tell you) to do with G-CSF, and none to SBH.

To: Mudcat who wrote (21897)	6/5/1998 1:31:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I would be virtually certain that LGND owns the Science and patents. SBH may have contributed a library of compounds to screen (the authorship on the Science paper should address your questions fairly directly).

To: Mudcat who wrote (21897)	6/5/1998 4:36:00 PM
From: Henry Niman	Respond to of 32384

Here's the abstract (by Ligand not SBH scientists): Discovery Of A Small Molecule G-Csf Mimic Jonathan I. Rosen, Ph.D., Senior Director, Transcription Research and New Leads Discovery, Ligand Pharmaceuticals, Inc. The JAK/STAT signal transduction pathway utilized by many cytokines can be exploited to develop high throughput screens for small molecule cytokine modulators. We applied this approach to the discovery of G-CSF mimics and have identified a non-peptidyl small molecule capable of activating granulocyte-colony stimulating factor (G-CSF) signal transduction pathways. This compound induces both the biochemical and cellular phenotypic responses characteristic of G-CSF. Remarkably, this compound is active in vivo with an efficacy similar to recombinant G-CSF. The identification of this compound provides proof of principle for drug discovery using JAK/STAT-based assays, and shows for the first time that a small non-peptidyl molecule can trigger the selective activation of a protein hormone receptor.